Leerink Partners on Rhythm Pharmaceuticals (RYTM): CHMP's positive opinion, language shows potential for broad EU labeling
March 26, 2026 2:50 PM
Leerink Partners analyst Thomas J. Smith reiterated an Outperform rating and $142.00 price target on Rhythm Pharmaceuticals (NASDAQ: RYTM)The analyst ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
